Skip to main content
Clinical Trials/NCT01225159
NCT01225159
Terminated
Not Applicable

Safety and Efficacy of Tight Glycaemic Control During Cardiac Surgery

Prince of Songkla University1 site in 1 country200 target enrollmentSeptember 2008

Overview

Phase
Not Applicable
Intervention
TGC
Conditions
Nosocomial Infection
Sponsor
Prince of Songkla University
Enrollment
200
Locations
1
Primary Endpoint
Nosocomial Infection
Status
Terminated
Last Updated
10 years ago

Overview

Brief Summary

To determine whether intraoperative tight glycaemic control can reduce postoperative infection, morbidity and mortality

Detailed Description

Hyperglycaemia develops frequently in patients undergoing cardiac surgery, especially following cardiopulmonary bypass (CPB). Recent evidence suggests that acute hyperglycaemia adversely affects immune function, wound healing and cardiovascular function.

Registry
clinicaltrials.gov
Start Date
September 2008
End Date
March 2009
Last Updated
10 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Panthila Rujirojindakul

Assistant Professor

Prince of Songkla University

Eligibility Criteria

Inclusion Criteria

  • age \> 15 years
  • cardiac surgery with cardiopulmonary bypass

Exclusion Criteria

  • active infection
  • insulin allergy
  • off-pump cardiopulmonary bypass procedures

Arms & Interventions

Tight glycaemic control (TGC)

TGC used hyperinsulinaemic normoglycaemic clamp with modified glucose-insulin-potassium to control blood sugar. The insulin (HumulinTM R, Lilly pharma, Germany) was diluted with normal saline to the concentration 1 IU. mL-1 and was infused continuously throughout the operations at a fixed rate of 0.3 IU. kg-1.h-1 but the maximal rate was 20 IU/ h. A separate mixture of glucose 25% (A.N.B Laboratories, Thailand) 50 mL, potassium chloride (Nida pharma, Thailand) 20 mEq and magnesium sulfate (Atlantic, Thailand) 2 gm was infused at 0.75 mL.kg-1.h-1 and was adjusted to maintain blood glucose levels 80-150 mg/dL.

Intervention: TGC

Conventional glycaemic control (Control)

Conventional glycaemic control aims to control blood sugar less than 250 mg%. Insulin was given bolusly if the blood sugar more than 250 mg%.

Intervention: Conventional glycaemic control

Outcomes

Primary Outcomes

Nosocomial Infection

Time Frame: within the first 30 day after surgery

Infection rate referred to the rate of nosocomial infection, including pneumonia, central line infection, surgical wound infection, deep sternal wound infection, urinary tract infection, and sepsis. Infections were defined according to the Centers for Disease Control and Prevention (CDC) definitions, occurring within 30 days postoperative cardiac surgery.

Secondary Outcomes

  • Morbidities and All Causes Mortality(within the first 30 days after surgery)

Study Sites (1)

Loading locations...

Similar Trials